Towards a New Way of Evaluating Orphan Drugs at CADTH

In Uncategorized by Karina Kusova

McKesson Canada is the leading provider of market access services connecting patients to orphan drugs and other drug therapies within the Canadian health care market. Through partnerships with manufacturers and extensive relationships with payers, providers, and patient groups, we create pathways that enable patient access to drug therapies, when and where they are needed.

An integral component of our approach is engaging with manufacturers to create effective market access strategies for a wide range of therapeutic areas. Our in-house Consulting Services team, led by Nabil Tadros (PharmD), is well-respected within the industry and has tremendous depth and breadth of experience, acquired through over 1,000 consulting, risk management, clinical trial, and patient services initiatives with over 100 industry-leading clients.

Download whitepaper here >>

An example of McKesson’s thought leadership in Rare Disease is our recent White Paper (attached),  Towards a New Way of Evaluating Orphan Drugs at CADTH. CADTH is a significant, national organization in Canada that evaluates therapies and makes recommendations on reimbursement. As such, it is important that manufacturers – especially orphan drug manufacturers who are new to Canada – understand how CADTH evaluates drug therapies.

We would be delighted to speak to you further about our expertise in this area at the upcoming World Orphan Drug Congress in Washington, DC and look forward to meeting.

Download whitepaper here>>

For more information, please contact;

Nabil Tadros, PharmD
Senior Manager, Consulting Services
McKesson Canada
289 247-3252


Alison Anisef
Director, BD Specialized Distribution
McKesson Canada
514 832-8052